{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T20:59:40Z","timestamp":1770325180904,"version":"3.49.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009093","name":"Fundaci\u00f3n Espa\u00f1ola de Hematolog\u00eda y Hemoterapia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.blre.2021.100865","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T19:22:11Z","timestamp":1624562531000},"page":"100865","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Past, present and future of prognostic scores in follicular lymphoma"],"prefix":"10.1016","volume":"50","author":[{"given":"Pablo","family":"Mozas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Rivero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando","family":"L\u00f3pez-Guillermo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2021.100865_bb0005","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France","author":"Swerdlow","year":"2017"},{"key":"10.1016\/j.blre.2021.100865_bb0010","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.19.01073","article-title":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study","volume":"37","author":"Bachy","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100865_bb0015","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/bjh.15708","article-title":"Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era","volume":"184","author":"Rivas-Delgado","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100865_bb0020","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100865_bb0025","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/bjh.14831","article-title":"Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group","volume":"178","author":"Alonso-\u00c1lvarez","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100865_bb0030","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1586\/ehm.09.34","article-title":"Prognostic tools in follicular lymphomas","volume":"2","author":"Luminari","year":"2009","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2021.100865_bb0035","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1161\/CIRCULATIONAHA.106.672402","article-title":"Use and misuse of the receiver operating characteristic curve in risk prediction","volume":"115","author":"Cook","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.blre.2021.100865_bb0040","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00277-017-3154-z","article-title":"Current prognostic and predictive factors in follicular lymphoma","volume":"97","author":"Sorigu\u00e9","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2021.100865_bb0045","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/0360-3016(84)90028-2","article-title":"Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret hospital experience","volume":"10","author":"Gospodarowicz","year":"1984","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.blre.2021.100865_bb0050","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1200\/JCO.1991.9.2.211","article-title":"Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy","volume":"9","author":"Coiffier","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100865_bb0055","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/annonc\/2.suppl_2.123","article-title":"Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years","volume":"2","author":"Bastion","year":"1991","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2021.100865_bb0060","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/oxfordjournals.annonc.a058044","article-title":"The identification of discrete prognostic groups in low grade non-Hodgkin\u2019s lymphoma","volume":"2","author":"Leonard","year":"1991","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2021.100865_bb0065","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/0277-5379(91)90425-D","article-title":"Low-grade follicular lymphomas: analysis of prognosis in a series of 281 patients","volume":"27","author":"Soubeyran","year":"1991","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1016\/j.blre.2021.100865_bb0070","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1200\/JCO.1991.9.5.762","article-title":"Follicular low-grade lymphoma: a risk model","volume":"9","author":"Romaguera","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100865_bb0075","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/10428199309147361","article-title":"Identification of prognostic groups in follicular lymphoma","volume":"10","author":"Cameron","year":"1993","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2021.100865_bb0080","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/0959-8049(95)00635-4","article-title":"The follicular non-Hodgkin\u2019s lymphomas - II. Prognostic factors: what do they mean?","volume":"32","author":"Denham","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.blre.2021.100865_bb0085","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","author":"International Non-Hodgkin\u2019\u2019s Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2021.100865_bb0090","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.1994.12.7.1343","article-title":"Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma","volume":"12","author":"L\u00f3pez-Guillermo","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100865_bb0095","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood.V85.12.3671.bloodjournal85123671","article-title":"Prognostic value of cellular proliferation and histologic grade in follicular lymphoma","volume":"85","author":"Martin","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100865_bb0100","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood.V86.4.1460.bloodjournal8641460","article-title":"International prognostic index for aggressive non-Hodgkin\u2019s lymphoma is valid for all malignancy grades","volume":"86","author":"Hermans","year":"1995","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2021.100865_bb0105","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. The Non-Hodgkin\u2019s Lymphoma Classification Project","volume":"89","author":"The Non-Hodgkin\u2019\u2019s Lymphoma Classification Project","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100865_bb0110","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1200\/JCO.1999.17.8.2499","article-title":"Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients - a study of the groupe d\u2019etude des lymphomes de l\u2019adulte","volume":"17","author":"Decaudin","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100865_bb0115","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100865_bb0120","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s12185-010-0674-x","article-title":"Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful?","volume":"92","author":"Solal-C\u00e9ligny","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2021.100865_bb0125","first-page":"783","article-title":"Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases","volume":"95","author":"Federico","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100865_bb0130","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/annonc\/mdi269","article-title":"Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems","volume":"16","author":"Perea","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2021.100865_bb0135","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2006-01-013367","article-title":"The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vinc","author":"Buske","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100865_bb0140","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","author":"Bachy","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100865_bb0145","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/annonc\/mds429","article-title":"Examination of the follicular lymphoma international prognostic index (FLIPI) in the national lymphocare study (NLCS): a prospective US patient cohort treated predominantly in community practices","volume":"24","author":"Nooka","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2021.100865_bb0150","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/annonc\/mdh406","article-title":"Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression","volume":"15","author":"Montoto","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2021.100865_bb0155","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1600-0609.2005.00564.x","article-title":"Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients","volume":"76","author":"Plancarte","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2021.100865_bb0160","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/annonc\/mdl162","article-title":"The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma","volume":"17","author":"Gin\u00e9","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2021.100865_bb0165","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1182\/blood.V126.23.3912.3912","article-title":"Predicting time to treatment in follicular lymphoma using population-based data","volume":"126","author":"Patmore","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100865_bb0170","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/bjh.16872","article-title":"The investigation and management of follicular lymphoma","volume":"191","author":"McNamara","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100865_bb0175","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100865_bb0180","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100865_bb0185","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100865_bb0190","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","author":"Dreyling","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2021.100865_bb0195","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/bloodadvances.2019032136","article-title":"Impact of age on clinical risk scores in follicular lymphoma","volume":"3","author":"Alig","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2021.100865_bb0200","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/bjh.16692","article-title":"The simplified follicular lymphoma PRIMA-prognostic index is useful in patients with first-line chemo-free rituximab-based therapy","volume":"191","author":"Kimby","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100865_bb0205","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/1097-0142(197403)33:3<870::AID-CNCR2820330337>3.0.CO;2-6","article-title":"Multivariate analysis of prognostic factors in the non-Hodgkin\u2019s malignant lymphomas","volume":"33","author":"Bloomfield","year":"1974","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2021.100865_bb0210","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/1097-0142(19880201)61:3<441::AID-CNCR2820610306>3.0.CO;2-N","article-title":"Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin\u2019s lymphoma: a randomized prospective study with an assessment of prognostic factors","volume":"61","author":"Steward","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2021.100865_bb0215","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1200\/JCO.1993.11.4.644","article-title":"Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy","volume":"11","author":"Dana","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100865_bb0220","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1365-2141.2004.05046.x","article-title":"Bone marrow histological patterns can predict survival of patients with grade 1 or 2 follicular lymphoma: a study from the Groupe d\u2018Etude des Lymphomes Folliculaires","volume":"126","author":"Canioni","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100865_bb0225","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s12185-016-2099-7","article-title":"FCG (FLIPI, Charlson comorbidity index, and histological grade) score is superior to FLIPI in advanced follicular lymphoma","volume":"104","author":"Mihaljevic","year":"2016","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2021.100865_bb0230","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/annonc\/mdp053","article-title":"Validation, revision and extension of the Follicular Lymphoma International Prognostic Index (FLIPI) in a population-based setting","volume":"20","author":"van de Schans","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2021.100865_bb0235","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-021-04470-7","article-title":"Age and comorbidity are determining factors in the overall and relative survival of patients with follicular lymphoma","author":"Mozas","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2021.100865_bb0240","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-019-0269-6","article-title":"Enhancement of the Follicular Lymphoma International Prognostic Index (FLIPI) with lymphopenia (FLIPI-L): a predictor for overall survival and histologic transformation","volume":"9","author":"Yang","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2021.100865_bb0245","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1016\/S2352-3026(18)30090-5","article-title":"Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis","volume":"5","author":"Federico","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2021.100865_bb0250","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/ajh.25973","article-title":"Follicular Lymphoma Evaluation Index (FLEX): a new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy","volume":"95","author":"Mir","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2021.100865_bb0255","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2021.100865_bb0260","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/S2352-3026(17)30078-9","article-title":"Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial","volume":"4","author":"Davies","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2021.100865_bb0265","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/ajh.23708","article-title":"The impact of race, age, and sex in follicular lymphoma: a comprehensive SEER analysis across consecutive treatment eras","volume":"89","author":"Nabhan","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2021.100865_bb0270","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/bjh.13502","article-title":"Clinico-biological features, treatment and survival of 457 patients with histological grades 3A and 1-2 follicular lymphoma mostly treated with immunochemotherapy","volume":"172","author":"Mercadal","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100865_bb0275","first-page":"1","article-title":"A clinico-genotypic prognostic index for de novo composite diffuse large B-cell lymphoma arising from follicular lymphoma in Asian patients treated in the rituximab era","volume":"10","author":"Lim","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.blre.2021.100865_bb0280","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2021.100865_bb0285","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/hon.2437_85","article-title":"Evaluation of clinicogenetic risk models for outcome of follicular lymphoma patients in the PRIMA trial","volume":"35","author":"Huet","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.blre.2021.100865_bb0290","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/blood-2019-130208","article-title":"Evaluation of the m7-FLIPI in patients with follicular lymphoma treated within the gallium trial: EZH2 mutation status may be a predictive marker for differential efficacy of chemotherapy","volume":"134","author":"Jurinovic","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100865_bb0295","first-page":"1","article-title":"M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy","author":"Lockmer","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100865_bb0300","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1182\/blood-2017-07-737353","article-title":"The promises and challenges of using gene mutations for patient stratification in follicular lymphoma","volume":"130","author":"Weigert","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100865_bb0305","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.blre.2019.03.006","article-title":"Recent landmark studies in follicular lymphoma","volume":"35","author":"Sorigu\u00e9","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2021.100865_bb0310","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100865_bb0315","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood-2020-142000","article-title":"Evaluation of the different stratification models for POD24 prediction in patients with follicular lymphoma","volume":"136","author":"Wu","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100865_bb0320","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1182\/bloodadvances.2020002546","article-title":"Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models","volume":"4","author":"Alig","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2021.100865_bb0325","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","article-title":"A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts","volume":"19","author":"Huet","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2021.100865_bb0330","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2020008119","article-title":"Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma","author":"Bolen","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100865_bb0335","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies","volume":"34","author":"Meignan","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100865_bb0340","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.2012.43.0934","article-title":"Impact of [18F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte and GOELAMS","volume":"30","author":"Dupuis","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100865_bb0345","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1200\/JCO.2017.74.1652","article-title":"Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma","volume":"36","author":"Luminari","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100865_bb0350","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1182\/blood-2017-11-816298","article-title":"Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA\/FIL study","volume":"131","author":"Cottereau","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100865_bb0355","doi-asserted-by":"crossref","DOI":"10.1200\/JOP.19.00691","article-title":"Potential of circulating tumor DNA for the management of patients with lymphoma","author":"Huet","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.blre.2021.100865_bb0360","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2020-139830","article-title":"Bayesian network modelling as a new tool in predicting of the early progression of disease in follicular lymphoma patients","volume":"136","author":"Proch\u00e1zka","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100865_bb0365","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood.V91.8.2955.2955_2955_2960","article-title":"The clinical significance of molecular response in indolent follicular lymphomas","volume":"91","author":"L\u00f3pez-Guillermo","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100865_bb0370","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2141.1975.tb00911.x","article-title":"The histopathology of malignant lymphoma","volume":"31","author":"Lennert","year":"1975","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100865_bb0375","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","article-title":"Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study","volume":"112","author":"Salles","year":"2008","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X21000710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X21000710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:27:53Z","timestamp":1759436873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X21000710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":75,"alternative-id":["S0268960X21000710"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2021.100865","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Past, present and future of prognostic scores in follicular lymphoma","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2021.100865","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100865"}}